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Background: Maternal blood folate concentrations during pregnancy have been
previously linked with DNA methylation patterns, but this has been done predominantly
through observational studies. We showed recently in an epigenetic analysis of the first
randomized controlled trial (RCT) of Folic Acid Supplementation specifically in Second
and Third Trimester (The EpiFASSTT Trial) that methylation at some imprinted genes
was altered in cord blood samples in response to treatment. Here we report on
epigenome-wide screening using the Illumina EPIC array (~850,000 sites) in these
same samples (n=86).
Results: The top-ranked differentially-methylated promoter region (DMR) showed a
gain in methylation with folic acid (FA) and was located upstream of the imprint
regulator ZFP57. Differences in methylation in cord blood between placebo and folic
acid treatment groups at this DMR were verified using pyrosequencing. The DMR also
gains methylation in maternal blood in response to FA supplementation. We also found
evidence of differential methylation at this region in an independent RCT cohort, the
AFAST trial. By altering methylation at this region in two model systems in vitro we
further demonstrated that it was associated with ZFP57 transcription levels.
Conclusions: These results strengthen the link between folic acid supplementation
during later pregnancy and epigenetic changes and identify a novel mechanism for
regulation of ZFP57. This trial was registered 15th May 2013 at www.isrctn.com as
ISRCTN19917787.
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MS TITLE: ¬A randomized controlled trial of folic acid intervention in pregnancy
highlights a putative methylation-regulated control element at ZFP57
Response to Reviewers
We would like to thank the reviewers for their positive feedback and constructive
criticisms provided, and we appreciate the time they have spent reviewing the
manuscript. In regards to their concerns, we have made alterations in blue in the
revised version, and responded to each point raised individually as further detailed
below. In summary, particular changes and new data to note in the revised MS are:-
-A revised Fig.1 showing exclusion/attrition from each arm of the study
-A new table of the top 5 ranked sites (Fig.2D) including verification (Results, p7)
-Further information on top-ranked regions including verification of one (Results, p8)
-More experimental detail on the data handling methods used to find and correct for
confounders etc (p21)
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Reviewer #1
We are very appreciative of the encouraging comments regarding the importance of
the findings in the manuscript, the suitable study design, appropriate controls and the
strength of our further comprehensive approach in terms of pyrosequencing, the use of
in vitro models and the verification of our findings in another independent RCT.
Major comments
C1. -Throughout the manuscript, the authors did not strongly rely on p-values for the
identification of differentially methylated regions, which can actually be considered a
strength. Identification of differentially methylated regions is based on ranking
(considering the RnBeads methylation measures and p-values). However, in order to
be able (for the reader) to evaluate the effects observed, it would be helpful to provide
some information on the p-values. Not providing this information (even when the
statistical approaches are not driven by p-values) raises the question whether the
finding were statistically significant. In Figure 3A, p-values were given for the top-5
differentially methylated regions at promoters. Were these p-values adjusted for
multiple testing?
R1. -The reviewer is correct that we are not reliant on p values for identifying the
differentially methylated regions of interest, but instead use the RnBeads rank as our
initial springboard for exploring regions with biologically meaningful differences.  The p
values were generated from linear models employed in the limma package and these
were not adjusted, which we now state in the text and legend: these are provided for
comparison purposes only and it can be seen that the top regions are not ordered from
lowest to highest, since the second-ranked gene has a lower p-value than the top-
ranked one.
Just to expand on why ranking was used instead, this measure is a combination of the
change in mean methylation (also known as the delta beta for EPIC arrays), the
quotient of mean methylation and the combined p value as stated on p6 at first use,
and in Methods under Statistical analysis (p22). To highlight this, we have included an
extra sentence on p6 (L22ff) to further explain our choice of ranking over p value alone.
The ranking approach in RnBeads was developed by Assenov and colleagues to
provide a more integrated measure, since sites with very good p values often have
very small differences in methylation which have little biological meaning; likewise, the
quotient may be very high, e.g. between 5% and 1% methylation, but the absolute
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change low. Where dealing with individual sites, the ranking system integrates the
absolute change, the quotient and the p value to come up with a single measure, for
example when looking at the top 1000 sites in Fig.2A and described on p6. We have
now included a table of the top-ranked sites as Fig.2D and a brief discussion of these
on p7 in response to both reviewers.
While ranking is our initial way of screening differentially methylated sites and regions,
the second most important feature for us was the % change in methylation, as only
sites showing differences which are 5% or greater can be reliably verified using
pyrosequencing: others, no matter how good the p value or how high the rank, cannot
be verified by a second lab method. We therefore find that using ranking first, then %
change, we can reliably verify differential methylation in our systems; p value would
then only be used as a third criteria if so wished. While examining the top-ranked sites
also uncovered some of interest, analysis at a site level (whether by rank or p value) is
less reliable, since these are more prone to artefacts due to the presence of SNPs and
show poorer correlation when assayed using pyrosequencing as described in the new
text (p7 L9ff)
Ranking can also be applied at the region level however as we had done in the case of
Fig.3A and here was based on the combination of the average difference in means
across all sites in the promoter regions of the sample groups, the mean of quotients in
mean methylation and the combined p-value, which was calculated from all site p-
values in the region using a generalization of Fisher's method as described in Methods
p22. In response to the reviewers, we have now also discussed the other top-ranked
regions in Fig.3A in more detail on p8 and explained why these were of less interest
than ZFP57, due to having low absolute levels of change in methylation, having
unknown functions, or similar (see p8, L6ff).
C2. -A major strength of the current study is that different approaches were used to
confirm the findings for the upstream region of ZFP57. Among the approaches used,
two different in vitro experiments were conducted to explore transcriptional
consequences of methylation changes in the upstream region. These experiments
may, however, not be well-equipped to draw firm conclusions about regulation of
ZFP57 expression. In the first experiment, knockout (KO) cells were used with a
mutation in DNMT1 and DNMT3b. As stated by the authors, these cells are
hypomethylated at many loci. The authors concluded that observed expression
changes of ZFP57 in these KO cells (as compared to wildtype) may be linked to
hypomethylation of the upstream region. The title of this results section says "The
upstream region is a methylation-dependent regulator of ZFP57 transcription".
However, as not only this upstream region, but many loci were hypomethylated, it
cannot be concluded whether (only the) upstream region regulates gene expression.
Similarly, in the second experiment, 5-aza-dC was used to perturb methylation in a
global manner. Also in this experiment, it is difficult to state whether the observed
differences in gene expression were (only) resulting from hypomethylation of the
identified upstream region. To conclude, both models lack specificity and may not be
fully suitable to study specific regulation of ZFP57 expression by the upstream region
identified.
R2. -While using isogenic cells with and without mutations in the methyltransferases
has been the gold standard to demonstrate a role for methylation in gene control, for
example in the case of imprinted genes (Li, Beard and Jaenisch Nature 366: 362
1993), X-inactivation (Beard, Li and Jaensich Gene Dev 9:2325 1995) and
endogenous retroviruses (Walsh, Chaillet and Bestor Nature genet 20:116 1998), it is
true that it is hard to formally exclude an indirect effect through change at some second
locus.  We minimised this risk by using biochemical inhibition of the methyltransferases
in a second cell line as well, reducing the likelihood that indirect effects are
responsible. However ideally we would need to alter methylation specifically at the
DMR using an epiCRISPR approach (while screening for off-target effects) and also
firmly establish the role of the DMR in control of ZFP57 transcription: these extensive
studies have just begun and will form the basis as a follow-up manuscript as referred to
on P16, L8 and also P17, L16ff. Acknowledging these limitations, we have reworded
the title of this section to read “Demethylation of the upstream region was accompanied
by increased ZFP57 transcription” (p9, L10ff) and the abstract to read “By altering
methylation at this region in two model systems in vitro we further demonstrated that it
was associated with ZFP57 transcription levels.” Likewise we have altered the MS title
to read “…highlights a putative methylation-regulated….”
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C3 Moreover, it would be of specific interest to study the effects of methylation gain
(rather than loss) in the current models and to consider folic acid as a potential
modulator of methylation at this region.
R3 - We agree with the reviewer that this would indeed be of real interest and have
made some attempts to modulate levels of folate in a cell line. While we have generally
seen some small methylation increase at this DMR upstream of ZFP57 upon folic acid
treatment the results have been variable and not sufficiently well reproducible. This
approach appears to be difficult and not representative of the physiological response to
folic acid supplementation due to the complexity of the one carbon metabolism cycle in
vivo, with its reliance on several essential cofactors and tissue interactions (see ref 2).
C4-The authors mentioned that the identified DMR upstream of ZFP57 was previously
reported in an observational study by Amarasekera et al (ref 52), which, together with
results from MoBa+ Generation R, support this region 'being a true folate-sensitive
DMR'. However, the results by Amarasekera point towards hypomethylation in women
with a high folate status, whereas in the current study a gain in methylation was found
with higher folic acid intake. These results therefore seem contradictive. Do the authors
have an explanation for this?
R4. -It is true that the Amarasekara study found mothers with higher FA intake had
lower methylation at this DMR rather than gains in methylation: in the MoBa +
Generation R study, sites at this region were confirmed as having differences, but no
direction or magnitude of change was stated, it may have been gain or loss. These
studies differed in sample size, design and analysis methods from ours, with the crucial
difference being that our results are from a randomized controlled trial (RCT) which can
look experimentally at whether increasing FA in mothers causes in methylation or not,
whereas the previous studies were observational and so could not examine whether
there was a causal link between increased maternal folate and increased offspring
DNA methylation of specific genes, even with a large sample size. A more relevant
comparison for us was the AFAST study, which was also an RCT where mothers were
supplemented with folic acid: in this cohort too there was a gain in methylation at the
ZFP57 DMR (Fig.5) in response to increasing the levels of folate in mothers, consistent
with our results. Finally, we also checked the response to FA in maternal bloods in our
own cohort, which is a semi-independent population. This again showed that
supplementation gave a gain in methylation at the ZFP57 DMR between the start of the
intervention (GW14) and the last time-point assessed (GW36) of +5.51% (Table 2);
strikingly, this was even similar in magnitude to the change seen in the offspring (cord
bloods). Given the good agreement in direction and magnitude of change at the ZFP57
DMR in the mothers, the offspring and in the AFAST offspring, all of which are RCT
cohorts, we feel this strongly supports there being a gain in methylation rather than
loss in response to FA supplementation.
While the design is the main and critical difference between the studies, we also note
the very high levels of serum folate concentrations in the high intake group in the
Amarasekara study (see next point below for more detail).
Minor comments
C5 General: Presumably, all women took folic acid before conception and during the
first trimester (for the prevention of NTDs). For women in the placebo group, this
means that they actively stopped taking folic acid at time of the current study. To what
extent can observed differences be attributed to this acute stop (and potentially decline
in folate status, see post-intervention values Table 1) rather than prolonged use
(versus a placebo)? Could this explain some of the observed findings (e.g. decline in
methylation for the placebo group in Table 2)? Could the authors speculate on this
aspect in more detail?
R5. While it is interesting to view it this way, there are some solid reasons why it would
be erroneous to do so.  Although Reviewer 1 is quite correct that all the women
included in this trial reported that they had taken folic acid supplements in the first
trimester, this relied on retrospective self-reported usage of folic acid; in this way the
first trimester of pregnancy is outside the period investigated in our RCT. This RCT of
folic acid supplementation starts at the beginning of the second trimester (not before
then); women at this point were randomized to receive either folic acid or placebo, with
the active treatment (intervention) therefore being folic acid. We cannot consider this to
be a trial of withdrawal of FA supplements in trimesters 2 and 3 because we did not
provide and control the supplement usage during trimester 1 (before randomization),
we simply recorded what participants reported to us.
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The values in Table 1 do show a decline in folate levels without ongoing folic acid
supplementation in the placebo group: this is a widely-reported effect observed during
pregnancy in larger observational studies, which would have included women both
taking and not taking FA in first trimester (see work cited in ref 42), so we are not
seeing any unusual effect in the placebo group due to an abrupt stop in FA, but rather
the results are in line with a range of previous studies showing that folate levels drop
during pregnancy. What we can say with certainty, due to this being an RCT, is that
1)the levels of folate in the placebo and treated groups were not different at the start of
the trial; 2)the levels drop in the placebo group (from 48.8 to 23.6 nmol/L in serum
comparing GW14 and GW36), in line with all previous observational work and 3)the
levels in the treated group are not elevated over normal but rather are protected from
this drop by the dietary supplementation (45.8 nmol/L at  GW14 and 46.5 nmol/L at
GW36). We have added a few lines to the Results (p5 L24ff) to highlight this point. See
also our previous papers on our RCT (refs 42 and 43) and literature cited therein for a
fuller discussion of this point.
Just to note that the normal levels of folate in our treatment group at GW36 is another
point of difference between our RCT and the observational study by Amarasekera et al,
where the high folate group they chose represented an extreme of the population and
had blood folate levels almost twice those seen in our treated group at the end of the
intervention (74.59+/- 6.1 nmol Amarasekera vs 46.5 +/-19.5 nmol/L GW36 treated
group (Table1)). We have added some sentences to the Discussion at the relevant
point to highlight this and other differences with the named study (p14, L5ff).
C6-Results: did a Manhattan (or Volcano) plot reveal any (potential) interesting sites?
R6. - Manhattan or volcano plots normally are used to identify sites with high p values:
as indicated above, we are using instead a ranking approach, but in response to this
request, and a similar one from Reviewer 2, we have provided instead a table of the
top-ranked differentially methylated sites (Fig.2D) as mentioned above. We describe
these and also provide data on those which we have verified in the revised Results
section (p7, L9ff).
C7-Abstract: page 2, line 7-8. "Maternal blood folate concentrations during pregnancy
have been previously linked with DNA methylation changes". 'Changes' can be
removed (or replaced by profiles / patterns).
R7 This has now been edited from ‘changes’ to ‘patterns’.
C8 Abstract: page 2, line 28-29. "Differences in methylation in cord blood between
groups...". The definition of groups have not been given before in the abstract. Please
explain what the groups are (FA versus placebo) in the abstract.
R8 This now reads as ‘Differences in methylation in cord blood between placebo vs
folic acid treatment groups.’
C9 Abstract, page 2, line 31-32. "... were verified using pyrosequencing, and the region
responds to FA supplementation in cord blood". The latter part of this sentence is not
clear. Should this be maternal blood (although in that case, the sentence is still not
very clear)?
R9 This has now been changed to “….were verified using pyrosequencing. The DMR
also gains methylation in maternal blood in response to FA supplementation.”
C10 Abstract: page 2, line 38-39. "By altering methylation at this region in two model
systems in vitro, we further demonstrated that it regulated ZFP57 transcription." Based
on the current experiments, it cannot be concluded whether this region regulated
ZFP57 transcription, only whether or not there was an association with ZFP57
transcription.
R10 This has now been changed to "By altering methylation at this region in two model
systems in vitro, we further demonstrated that it was associated with ZFP57
transcription."
C11 Methods: Were any potential confounders considered in the differential
methylation analyses?
R11 We controlled for both known and unknown confounders using a number of
approaches: we have expanded this section of the methods to elaborate (p21, L2ff) as
follows:
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“Initial data exploration in RnBeads used principle components analysis (PCA) to
explore potential correlations between the groups and known confounders such as
BMI, smoking, gender etc. In addition, in order to account for any hidden confounding
variables in the dataset, surrogate variable analysis was carried out using the sva
package with the Buja and Eyboglu algorithm from (1992) [68]. Briefly, potential
surrogate variables such as age, sample plate, Sentrix ID and Sentrix Position were
tested for association with the target variable sample group using PCA  and any
surrogate variable with a high correlation to sample group was adjusted for and
incorporated into the making of the limma based linear model.“
C12 Results: page 5, line 48-50. Minor suggestion: Red Cell Folate without capitals.
'also' can be removed from this sentence.
R12 This has been amended.
C13 Results: page 7, line 37-40. Not clear why the authors refer to figure 3C in this
sentence. The numbers mentioned in this sentence (6.23%) refer to panel 3A.
R13 Corrected to Fig.3A.
C14 Results: page 9, line 39-40. 'samples' is presumably subjects (or participants /
women).
R14 This has been amended to read ‘participants’
C15 Discussion: page 13, line 21-22. Minor typo: examined = examine.
R15 Corrected
C16 . -Results: why is a p-value given for the methylation differences assessed by the
pyrosequencing assay (in Figure 3C), but not for the maternal methylation values (in
Table 2)?
R16. -The p values for the maternal methylation values in Table 2 were not significant:
this is now mentioned in the text on P11, L24.
C17-Figure 1: Presuming that some of the excluded women had actually started with
the intervention, it would be informative to present the reasons for exclusion (and
corresponding numbers) for both study arms separately.
R17. -Figure 1 now includes the numbers of women excluded from the study for each
arm (as below) and this has been further detailed in the methods.
C18 Figure 2a: label for the x-axis shifted to the right.
R18 This has been amended
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Reviewer #2:
This is an interesting and well-written study by Irwin and colleagues reporting a DMR
upstream of ZFP57 with increased methylation after folic acid supplementation.
Differences in methylation were verified using pyrosequencing. For this study
epigenome-wide screening was performed on samples from the EpiFASSTT trial. They
also found evidence of differential methylation at this region in an independent cohort,
the AFAST trial.
Just a few comments/suggestions:
C1 Background
Page 3, Line 22: The authors report some health benefits of FA supplementation but is
missing important background information. The maternal folate status was associated
with neural tube defect (NTD) risk as early as 40 years ago and up to 70% of NTDs
can be prevented by an optimal maternal red blood cell folate concentration,
information on neural tube defects and the benefits of FA supplementation is lacking.
[Greene et al, PMID: 21613818; Blom et al, PMID: 16924261; Rochtus et al, PMID:
26349489]
R1. -We thank the reviewer for bringing this to our attention. We have now included
these important and interesting references: “Despite the identification of a relationship
between maternal folate status and NTDs as early as 40 years ago, information on the
mechanism behind  between the benefits of FA supplementation with respect to NTDs
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remains to be fully elucidated (reviewed in [8]), as does the relationship of FA, NTDs
and DNA methylation [9]. There is however little dispute as regards the protective
effect of folic acid supplementation before and in early pregnancy, which was proven in
clinical trials to reduce NTDs by approximately 70% [10]. Furthermore”
C2 Page 3, Line 42: They write "At a molecular level, there is some evidence in human
that epigenetic changes could be the mechanism underpinning some of the effects of
folate, particularly in second and third trimester, as reviewed elsewhere." Several lines
of evidence support the link between NTDs and epigenetics; especially with an
impaired methylation cycle [Greene et al, PMID:21613818]. The neural tube closes in
the first trimester. Please elaborate.
R2. – We have added some text and cited this excellent review at the relevant point as
follows: “At a molecular level, there is some evidence in human that epigenetic
changes could be the mechanism underpinning some of the effects of folate, both in
the first trimester [8] in the prevention of NTDs, and also in second and third trimester,
as reviewed elsewhere [2].”
C3 Please elaborate how differential methylation of a region upstream of the imprinted
gene ZFP57 can influence transcription.
R3. –The region where the upstream DMR is located has some features characteristic
of a control element, as from examining publicly-available datasets on the UCSC
genome browser there are DNAse I hypersensitive sites present here and data
suggesting transcription factors may bind here. The potential function for this genomic
region is currently being explored in the lab in more detail. We have added a sentence
to the Discussion to highlight this information (p17, L16ff). In the Amarasekera paper
they found an association between hypomethylation of this DMR and increased
transcriptional activity of the ZFP57 gene, but did not test the effects of removing
methylation using cell lines and inhibitors as we have.
C4 Cell experiments were performed with HCT116 and HCT116 DKO cell lines. It
would be interesting to perform cell experiments to look for the influence of FA
supplementation? Were these experiments performed or can they be performed?
R4- See the response to C3 for Reviewer 1 above.
C5 Page 12, line 10: give reference of study that reported that maternal folate
concentrations in the third trimester were associated with changes at a DMR at a
similar location. What do you mean with similar, are these regions overlapping? Please
explain further.
R5. -We understand and apologise that this sentence is confusing, and for clarity we
have added the reference here and confirmed we are looking at the same DMR:
‘maternal folate concentrations in the third trimester were associated with changes at a
DMR at the same genomic location [56]’.
C6 Page 12, line 24: how can you conclude that this is a folate-sensitive DMR?
R6. There are a number of lines of evidence presented in the paper and from the
literature to support this point: 1)this region is the top differentially-methylated region in
cord blood in this randomized control trial of folic acid intake; 2)the region shows the
same direction and similar magnitude of response in offspring in a second RCT, the
AFAST cohort; 3)this DMR responds directly to FA in the treated mums; 4)the region
has been identified in a previous observational study (Amarasekera) and confirmed in
a meta-analysis (MoBa + GenR). This all supports it being a true folate-sensitive DMR.
C7Validation with pyrosequencing: please give absolute values and p-values of the
gain and loss of methylation.
R7 We have now included the gain of methylation and magnitude (p14 L18ff): “We
could also verify using a separate biological assay the magnitude and direction of
change in methylation, a gain of 5.44% in the treatment group, at the DMR in cord
blood by using pyrosequencing (p = 0.172).”
C8 Figure 2B: "Probe methylation density plot comparing the distributions of
methylation values per sample group. In the treatment group there is a decrease in the
number of fully methylated sites (β >0.75)." How can you explain that there is a
decrease in the number of fully methylated sites after FA supplementation? You would
expect the opposite.
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R8 –Although a decrease may seem counterintuitive, we and others have observed
this previously. For example, in the meta-analysis performed by Joubert et al. (2016)
regarding the MoBa and Generation R studies, there were more CpG with significantly
decreased methylation than increased (94% vs 6%). Likewise, we found decreased
methylation in response to FA at the high copy number interspersed element LINE1,
often used as a litmus test for genome-wide methylation (Caffrey et al, ref 43). The
biochemical reasons behind this are currently unclear, however literature suggests that
higher levels of FA may cause feedback inhibition by altering the SAM:SAH ratio and
therefore the intracellular methylation potential (Christensen et al., 2015).  We have
added some sentences to the Discussion clarifying this (p13 L8ff).
C8 Figure 3A: Top 5 differentially methylated regions: did the authors perform cell
experiments with the other genes? Please give more background information on these
genes and why they did (not) elaborate these genes.
R8. In response to the reviewers, we have now also discussed the other top-ranked
regions in Fig.3A in more detail on p8, L6ff and explained why these were of less
interest than ZFP57:
“For the top 5 regions, ZFP57 was of particular interest and is dealt with below. Two
others (CES1, a liver carboxylesterase, and ANKRD20A11P, a pseudogene) show less
than 5% change in methylation and so could not be verified: DUSP22 which has a
larger change is also a pseudogene and so of less interest. The last DMR is located at
a microRNA cluster MIR4520A/B and loses approximately 7.22% overall in the
treatment group, averaged over a number of well-spaced CG. Due to pyrosequencing
assay design constraints, we could only cover one site (cg08750459) from the array at
this locus but that site showed reasonable concordance (loss of 12.24% (p = 0.008) in
array and 9.45% (p = 0.006) by pyroassay). The function of these microRNA remains
obscure however. “
We now also present data on the top 5 ranking sites in Fig.2D, with data on their
verification and some discussion of their function on p7, L9ff
“We examined the top-ranking sites as identified by RnBeads (Fig.2D): of these, the
CG site in the ATP11A gene contained a single nucleotide polymorphism (SNP)
missed by the quality control routines: the same was true of the CG at the MAGI2
gene. The presence of the SNPs at these CGs leads to the erroneous appearance of a
change in methylation, so these were discounted. Two of the other top-ranked sites
were at the PRKAR1B locus, which encodes a regulatory subunit of cyclic AMP-
dependent protein kinase A, and one was at NXN, a member of the thioredoxin
superfamily: however all three were listed as located in the respective gene body and
so are less likely to contribute to transcriptional control. Nevertheless to verify these we
used a second method utilizing commercial pyrosequencing methylation assays
(pyroassays) designed to query the same CGs. These reported smaller average
differences in methylation between treated and placebo groups than seen with the
array of 6.6% for cg08104960 at NXN, and 4.2% (cg06242242) and 2.2% for
(cg05729249) for the sites at PRKAR1B: only the site at NXN was significant (p=0.002,
t-test). “
As the other targets are either in gene bodies, and thus unlikely to exert significant
transcriptional control, or have unknown function, we therefore concentrated on ZFP57,
which in addition to being the top hit and validated in another cohort, also is strongly
functionally linked to imprinting, and we have found differences in methylation at
imprinted loci in this cohort (this report and ref 43). This rationale is emphasized in the
Discussion (p13).
C9 All Figures: the layout of the Figures is nice, but please make them more uniform:
use same letter type for all Figures.
R9. -We would like to thank the reviewer for their kind comments regarding the figures
of the manuscript, and we have now made these more uniform as suggested.
Additional Information:
Question Response
<b>Is this study a clinical
trial?</b><hr><i>A clinical trial is defined
by the Word Health Organisation as 'any
Yes
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research study that prospectively assigns
human participants or groups of humans
to one or more health-related
interventions to evaluate the effects on
health outcomes'.</i>
We require registration of all clinical trials
that are reported in manuscripts submitted
to the journal. More information about trial
registration, including the trial registries
that currently meet all of the ICMJE
guidelines, can be found in the FAQ
section of "About ICMJE" at <a
href="http://www.icmje.org/about-
icmje/faqs/clinical-trials-registration/"
target="_blank">http://www.icmje.org/abo
ut-icmje/faqs/clinical-trials-
registration/</a>.<p>Please provide the
following information where
prompted:<hr>Enter the Trial Registration
Number:<br/>&emsp;as follow-up to
"<b>Is this study a clinical
trial?</b><hr><i>A clinical trial is defined
by the Word Health Organisation as 'any
research study that prospectively assigns
human participants or groups of humans
to one or more health-related
interventions to evaluate the effects on
health outcomes'.</i>"
ISRCTN19917787
Enter the name of the
registry:<br/>&emsp;as follow-up to
"<b>Is this study a clinical
trial?</b><hr><i>A clinical trial is defined
by the Word Health Organisation as 'any
research study that prospectively assigns
human participants or groups of humans
to one or more health-related
interventions to evaluate the effects on
health outcomes'.</i>"
ISRCTN
Enter the URL of the trial registry
record:<br/>&emsp;as follow-up to "<b>Is
this study a clinical trial?</b><hr><i>A
clinical trial is defined by the Word Health
Organisation as 'any research study that
prospectively assigns human participants
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Abstract  1 
Background: Maternal blood folate concentrations during pregnancy have been previously 2 
linked with DNA methylation patterns, but this has been done predominantly through 3 
observational studies. We showed recently in an epigenetic analysis of the first randomized 4 
controlled trial (RCT) of Folic Acid Supplementation specifically in Second and Third 5 
Trimester (The EpiFASSTT Trial) that methylation at some imprinted genes was altered in 6 
cord blood samples in response to treatment. Here we report on epigenome-wide screening 7 
using the Illumina EPIC array (~850,000 sites) in these same samples (n=86).  8 
Results: The top-ranked differentially-methylated promoter region (DMR) showed a gain in 9 
methylation with folic acid (FA) and was located upstream of the imprint regulator ZFP57. 10 
Differences in methylation in cord blood between placebo and folic acid treatment groups at 11 
this DMR were verified using pyrosequencing. The DMR also gains methylation in maternal 12 
blood in response to FA supplementation. We also found evidence of differential methylation 13 
at this region in an independent RCT cohort, the AFAST trial. By altering methylation at this 14 
region in two model systems in vitro we further demonstrated that it was associated with ZFP57 15 
transcription levels.  16 
Conclusions: These results strengthen the link between folic acid supplementation during later 17 
pregnancy and epigenetic changes and identify a novel mechanism for regulation of ZFP57. 18 
This trial was registered 15th May 2013 at www.isrctn.com as ISRCTN19917787. 19 
Keywords: Folic Acid; DNA methylation; Cord Blood; Offspring; Imprinting; ZFP57 20 
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Background 1 
Folate is an essential B-vitamin required for viable embryonic and fetal development and as an 2 
important dietary constituent throughout life, fundamental in cellular biosynthesis and DNA 3 
methylation pathways [1,2].  Folic acid (FA) is the oxidized, and more stable, synthetic form 4 
of folate which is exclusively found in supplements and fortified foods [3]. Well-established 5 
evidence from randomized controlled trials [4,5] has led to recommendations, in place globally, 6 
that women should consume 400µg/d FA from prior to conception until the end of the first 7 
trimester in order to protect against neural tube defects (NTDs) [6,7]. Despite the identification 8 
of a relationship between maternal folate status and NTDs as early as 40 years ago, information 9 
on the mechanism behind the benefit of FA supplementation with respect to NTDs remains to 10 
be fully elucidated (reviewed in [8]), as does the relationship of FA, NTDs and DNA 11 
methylation [9]. There is however little dispute as regards the protective effect of folic acid 12 
supplementation before and in early pregnancy, which was proven in clinical trials to reduce 13 
NTDs by approximately 70% [10]. Furthermore there remains a lack of evidence as to whether 14 
it is beneficial to mother and/or child to continue this supplementation throughout the entire 15 
pregnancy [11,12]. FA supplementation during pregnancy has been associated with health 16 
benefits such as reduced risk of low birth weight [13], language delay [14], autism [15], 17 
reduced risk of psychosis [16]  and other pediatric problems [17]. In addition, observational 18 
studies have indicated that FA supplement use by mothers during pregnancy is associated with 19 
better cognitive health and brain development in the child [14,18,19], possibly related to the 20 
fact that there is a brain growth spurt at the end of the second trimester [20,21]. However there 21 
may also be potential adverse effects from excess folate in later pregnancy, an aspect which 22 
would also benefit from further exploration [12]. 23 
At a molecular level, there is some evidence in human that epigenetic changes could be 24 
the mechanism underpinning some of the effects of folate, both in the first trimester [8] in the 25 
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prevention of NTDs, and also in second and third trimester, as reviewed elsewhere [2]. Folate 1 
is essential for the production of S-adenosylmethionine (SAM), which provides the methyl 2 
group to the DNA methyltransferases (DNMTs), which carry out DNA methylation. DNA 3 
methylation is an essential means of maintaining transcriptional silencing at many different 4 
classes of genes when it occurs at promoter and enhancer elements, including endogenous 5 
retroviruses, genes on the inactive X, and imprinted genes [22] but can also facilitate 6 
transcription when occurring in the gene body [23–25]. DNA methylation is vital for 7 
embryonic survival and development, as mice carrying mutations in the DNA 8 
methyltransferases die in utero or shortly after birth [26,27]. Some DNA methylation marks 9 
are inherited from the parents in the form of differential methylation on the paternal or maternal 10 
copy. This includes both the canonical imprinted loci, as well as some germline and neuronal 11 
genes [25,28,29], at all of which methylation plays a direct role in controlling transcription. 12 
Both animal and human studies have indicated that the fetal epigenome is vulnerable to 13 
environmental exposures, such as methyl group availability from the maternal diet [30–36]. 14 
Imprinted genes are a paradigm for transmission of epigenetic information across generations.  15 
Methylation differences between the paternal and maternal copies of imprinted genes are 16 
established in the germ cells and are known to be important for transcriptional regulation.  17 
Accordingly, inappropriate loss or gain of methylation at imprint control regions (ICR) is a 18 
diagnostic feature for several human disorders. These regions are protected from the wave of 19 
demethylation which occurs prior to implantation by several factors, such as PGC7/STELLA 20 
[37] and  ZFP57, a Krueppel-associated box (KRAB) domain zinc finger protein [38,39]. 21 
Several studies to date have centered on analyzing the effects of nutrition in particular on 22 
imprinted genes [31–33,40] and have shown that not only can altered diet result in an altered 23 
epigenotype, but it can also affect phenotype and predisposition to childhood and adulthood 24 
disease [41].  25 
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We have previously reported data from a randomized controlled trial of Folic Acid 1 
Supplementation in the Second and Third Trimester (The FASSTT Trial; ISRCTN19917787) 2 
where we found supplementation led to significant protection against folate depletion in 3 
mothers and offspring [42], and more recently that this led to differences in DNA methylation 4 
at some imprinted loci by using a candidate gene approach [43]. Here we used the Infinium 5 
Methylation EPIC Beadchip Array to profile genome-wide DNA methylation levels in cord 6 
blood in an unbiased screen for regions susceptible to DNA methylation changes in response 7 
to altered FA levels. We report here that the top candidate region affected is a differentially 8 
methylated region (DMR) upstream of the gene encoding ZFP57. We verified our finding using 9 
pyrosequencing in cord blood, and also show that the region responds to FA supplementation 10 
in maternal blood. Additionally, we confirm that altering methylation results in changes in 11 
ZFP57 transcription.   12 
Results 13 
Maternal FA supplementation significantly improves folate status in mother and baby 14 
For the current analysis, the same 86 cord blood samples from the FASSTT trial (outlined in 15 
Fig. 1) which had been analyzed previously for candidate gene methylation [43] were used: a 16 
summary of the most pertinent characteristics are given in Table 1 for convenience. At baseline 17 
(gestational week 14 (GW14)), there were no detectable differences between the treatment and 18 
placebo groups in maternal characteristics, dietary folate intakes, serum or red blood cell (RBC) 19 
folate concentrations, or in MTHFR status, as expected following randomization. There were 20 
also no significant differences in neonatal characteristics such as weight, length, head 21 
circumference etc (Table 1). However as a result of treatment with FA during trimesters 2 and 22 
3, maternal serum and RBC folate became significantly different between placebo and treated 23 
group, as previously reported from this trial. The normal decline in maternal folate biomarkers 24 
previously reported from observational studies during pregnancy are mirrored in the placebo 25 
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group where serum folate decreased from 48.8 to 23.6 nmol/L between GW14 and GW36 1 
(Table 1). FA supplementation served to protect the mothers in the treatment group, where 2 
folate concentrations remained stable over the course of pregnancy (i.e. serum folate 45.8 3 
nmol/L at GW14 and 46.5 nmol/L at GW36).  Cord serum and RBC folate concentrations were 4 
also significantly higher in infants of the mothers supplemented with FA compared with those 5 
from the placebo mothers (Table 1). RBC folate concentrations in mothers and offspring were 6 
strongly correlated (r = 0.619; P = <0.001, Suppl. Fig. 1). 7 
Widespread alterations to DNA methylation levels in cord blood in response to late 8 
gestation maternal FA supplementation  9 
DNA was purified from cord blood and quantified prior to bisulfite conversion and 10 
hybridization to the Infinium Methylation EPIC Beadchip Array, which covers more than 11 
850,000 CpG sites distributed across the genome. Methylation values are expressed as a 12 
decimal value β between 0.0 (no methylation) and 1.0 (fully methylated). Data were analyzed 13 
and visualized using the RnBeads package in RStudio (see methods section). As a control, a 14 
quantile-quantile (QQ) plot of observed versus expected Chi-squared values was generated and 15 
showed no evidence of population substructure effects (Suppl. Fig.2). Figure 2A is a scatterplot 16 
showing mean β value for each CpG site analyzed in treated versus placebo samples. Overall, 17 
methylation at individual CpG remains closely correlated (=0.998) between the two groups 18 
as expected, with most sites falling along the diagonal. Sites which differed in methylation 19 
between placebo and treatment groups were automatically ranked by RnBeads, which uses a 20 
combination of the change in mean methylation, the quotient of mean methylation and the 21 
combined p value, and the 1000 top-ranking sites are highlighted in red in Figure 2A. This 22 
metric was developed to take into account not only p value but the magnitude of the change in 23 
methylation and in our experience is a more reliable indicator of biologically meaningful 24 
differences than p value alone. Sites falling along either side of the diagonal, representing gains 25 
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and losses in methylation after treatment, can both be seen, with a tendency to greater numbers 1 
of sites losing. Consistent with this, a methylation density distribution plot shows that after 2 
treatment there was a clear decrease in the numbers of sites in the top quartile for methylation 3 
(β=0.75-1.00; Fig. 2B). Taking the top 1000 ranking sites overall, approximately 2/3 (n=658) 4 
lost and 1/3 (n=342) gained methylation (Fig. 2C). However, the magnitude of these changes 5 
was generally modest, with only 302 (193+109) losing or gaining more than 5% methylation, 6 
the minimum change which we could potentially verify using pyrosequencing, and only 76 7 
sites losing or gaining more than 10% (Fig. 2C).  8 
We examined the top-ranking sites as identified by RnBeads (Fig.2D): of these, the CG site in 9 
the ATP11A gene contained a single nucleotide polymorphism (SNP) missed by the quality 10 
control routines: the same was true of the CG at the MAGI2 gene. The presence of the SNPs at 11 
these CGs leads to the erroneous appearance of a change in methylation, so these were 12 
discounted. Two of the other top-ranked sites were at the PRKAR1B locus, which encodes a 13 
regulatory subunit of cyclic AMP-dependent protein kinase A, and one was at NXN, a member 14 
of the thioredoxin superfamily: however all three were listed as located in the respective gene 15 
body and so are less likely to contribute to transcriptional control. Nevertheless to verify these 16 
we used a second method utilizing commercial pyrosequencing methylation assays 17 
(pyroassays) designed to query the same CGs. These reported smaller average differences in 18 
methylation between treated and placebo groups than seen with the array of 6.6% for 19 
cg08104960 at NXN, and 4.2% (cg06242242) and 2.2% for (cg05729249) for the sites at 20 
PRKAR1B: only the site at NXN was significant (p=0.002, t-test).  21 
Identification and verification of a differentially methylated region upstream of ZFP57 22 
Given that single sites are more susceptible to confounders such as the presence of SNPs and 23 
show only moderate accuracy on verification, and to maximize our chances of finding 24 
biologically significant changes, we also looked for genomic intervals showing coherent 25 
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alterations in methylation across multiple neighboring sites [44], rather than isolated CpGs. 1 
Figure 3A lists the top 5 differentially methylated regions (DMR) found at promoters, ordered 2 
by RnBeads ranking which is here computed by combining measures at adjacent sites using a 3 
linear hierarchical model as described in Methods: uncorrected p value and % change in 4 
methylation are also shown for comparison. For the top 5 regions, ZFP57 was of particular 5 
interest and is dealt with below. Two others (CES1, a liver carboxylesterase, and 6 
ANKRD20A11P, a pseudogene) showed less than 5% change in methylation and so could not 7 
be verified: DUSP22 which has a larger change is also a pseudogene. The last DMR is located 8 
at a microRNA cluster MIR4520A/B and loses approximately 7.22% overall in the treatment 9 
group, averaged over a number of well-spaced CG. Due to pyrosequencing assay design 10 
constraints, we could only cover one site (cg08750459) from the array at this locus but that site 11 
showed reasonable concordance (loss of 12.24% (p = 0.008) in array and 9.45% (p = 0.006) by 12 
pyroassay). The function of these microRNA remains obscure however.  13 
Of more interest in the context of this cohort was the highest ranking promoter DMR identified 14 
using RnBeads [45], which was located on chromosome 6, the closest gene being the known 15 
regulator of genomic imprinting ZFP57. The identified DMR consisted of 15 CpG sites and 16 
mapped approximately 3kb upstream of the first exon of the gene, a region containing 17 
additional adjacent sites also gaining methylation. Figure 3B shows a genomic map of the first 18 
exon of ZFP57 and the upstream region, overlaid with a track showing the locations of EPIC 19 
probes and whether they gained or lost methylation. Also shown is a graph of averaged 20 
methylation values at the numbered CpG probes from the array in placebo and treatment 21 
groups, showing a clear difference in methylation extending beyond the DMR. To confirm 22 
these results using a second method we designed a pyrosequencing methylation assay 23 
(pyroassay) to cover some of these CpG sites, as shown in Fig.3B. Due to the CpG density of 24 
this region, thus difficulty in pyrosequencing primer design, our pyroassay is not directly 25 
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overlapping all CpGs identified by RnBeads as the DMR but is inside the area showing 1 
methylation differences. We then carried out PCR and pyrosequencing for all the samples. 2 
Methylation levels at each array site (n=15) in the DMR, averaged across each group are shown 3 
in Fig.3C. This confirmed clear differences between the two groups with respect to methylation 4 
across this region, with cord bloods from the children born to FA-supplemented mothers 5 
showing higher methylation at all sites, and 6.23% more methylation overall for the significant 6 
DMR probes (Fig.3A). The overall gain in methylation at the CpGs covered by the pyroassay 7 
(n=6) was very similar in magnitude and direction to that seen over the neighboring CpG by 8 
the array (+5.44% vs +6.23%, respectively- Fig.3A, C).   9 
Demethylation of the upstream region was accompanied by increased ZFP57 10 
transcription 11 
Having established that methylation differences at the upstream DMR are evident between FA-12 
supplemented and placebo-treated controls, we wished to test mechanistically if such 13 
differences could impact on transcription from the downstream gene. To do this, we first used 14 
a well-established model, the paired colorectal cancer lines HCT116 and its derivative HCT116 15 
DKO (double knockout), which carries mutations in two of the methyltransferase genes 16 
DNMT1 and DNMT3B and is known to be hypomethylated at many loci  [46]. Methylation 17 
array data available in-house showed differential methylation between the parental or wild type 18 
HCT116 (WT) and paired DKO cells at the same region upstream of ZFP57 found in the 19 
FASSTT cohort, indicated by red coloured bars whose height is proportional to the loss of 20 
methylation (Fig.4A); this indicates that DNMT1 and DNMT3B are required for methylation 21 
at this locus. We confirmed these results using our pyroassay, which showed >80% methylation 22 
in WT HCT116 cells and a drop to <20% in DKO cells (p<0.001) (Fig.4B).  23 
To determine if methylation at this upstream region can regulate transcription at the 24 
ZFP57 gene 3kb downstream, we designed primers to cover part of the transcript as shown in 25 
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Fig.5A (FW/RV) and carried out reverse transcription on mRNA from the cells followed by 1 
polymerase chain reaction (RT-PCR). While minimal transcript could be detected in the 2 
HCT116 WT cells, which are heavily methylated, signal was readily apparent in the 3 
demethylated DKO cells (Fig. 4C). We confirmed this expression pattern quantitatively using 4 
RT-qPCR (Fig.4D). While these results show that the gene can be de-repressed in response to 5 
loss of methylation, it is normally not expressed in colon cells, from which HCT116 were 6 
derived, so we used the neuroblastoma cell line SH-SY5Y to test the effect of methylation 7 
changes on transcription in a neural cell type. ZFP57 is normally transcribed in neural tissue 8 
as well as early embryo [47], but shows some methylation in the SH-SY5Y cells, which may 9 
be due to differences among neural cell types, or reflect accumulation of methylation during 10 
culture: however these cells are likelier than HCT116 to contain neural-specific transcription 11 
factors.  Here we used a second method to perturb methylation, namely treatment with the 12 
DNA methyltransferase inhibitor 5’aza-2’deoxycytidine (5-aza-dC). Exposure of the cells to 13 
this small molecule inhibitor caused loss of methylation at the upstream region (Fig.4E). RT-14 
PCR confirmed that ZFP57 was de-repressed upon treatment with 5-aza-dC (Fig.4F). 15 
Quantification of mRNA levels with RT-qPCR again indicated a substantial increase in 16 
transcription from the gene in response to loss of methylation (Fig. 4G). 17 
Greater variability at imprinted DMR in folate-treated samples 18 
These results suggest that the increased methylation seen at the ZFP57 upstream region will 19 
lead to a decreased transcription. Since ZFP57 plays a role in maintaining methylation 20 
specifically at imprinted genes, we examined methylation levels at these regions using data 21 
from the EPIC array. We used germline differentially methylated regions as defined by [48] 22 
and assessed average methylation across all probes which fell within these intervals. We 23 
excluded DMR which were flagged as acquiring methylation differences somatically, and also 24 
germline DMR where methylation as assessed by the array fell outside the 35-65% methylation 25 
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range defined as normal in that study. This left 15 imprinted germline DMR for which the 1 
median methylation level fell within the normal range in the placebo group (Suppl. Fig.3A). 2 
Comparing the samples from the folate supplemented group, only the maternally imprinted 3 
Neuronatin gene (NNAT) showed a small but significant loss of methylation in the treatment 4 
group (p=0.022, Mann-Whitney U test (MWU)) but there was no significant difference 5 
between placebo and treatment for any other DMR. However it was notable that 11/15 DMR 6 
showed a significantly greater variability in methylation in treated participants (p<0.001, Chi-7 
squared test), which can be seen from the greater interquartile range (IQR -see Suppl. Fig.3A). 8 
Along with this greater variability in the treatment group, the median methylation levels 9 
trended lower than the placebo group for almost all imprinted genes. (Suppl. Fig. 3A). We 10 
repeated this analysis using imprinted DMR as defined by Court et al [49], which defines 11 
slightly larger DMR based on an analysis of Illumina 450K data. After applying similar criteria 12 
as above, this left 14 DMR suitable for comparison. Using these genomic intervals, again only 13 
NNAT showed a significantly different level of methylation in treated samples (p=0.022, 14 
MWU; Supp.Fig.3B), although PLAG1 was also close to significant (p=0.072, MWU). Again, 15 
the IQR for the imprints showed greater variability in the treated than placebo groups (p<0.001, 16 
Chi-squared test) and medians tended to be lower in the FA-treated group (Suppl.Fig.3B).  17 
Increased ZPF57 methylation in response to FA in maternal blood samples 18 
In order to investigate the effects of FA in maternal tissue, and to elucidate if this differentially 19 
methylated region upstream of ZFP57 was directly responsive, we carried out pyrosequencing 20 
on matched maternal buffy coat samples at GW14 (n=24) and GW36 (n=24) (i.e. comparing 21 
the same mother’s blood sample taken before and after intervention). Pyrosequencing analysis 22 
confirmed that FA-supplemented mothers show a 5.51% increase in DNA methylation levels 23 
at this DMR after late gestation supplementation (p value not signif.), in contrast to non-24 
supplemented mothers, whose methylation levels decreased 1.51% at GW36 (Table 2). 25 
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 1 
Effect of FA at the ZFP57 DMR in a second cohort  2 
In order to test the generality of the effect of folic acid intervention on this genomic region, we 3 
examined data from a second randomized-controlled trial. The Aberdeen Folic Acid 4 
Supplementation Trial (AFAST) was an RCT  using two doses of folic acid (0.2 and 5mg/day 5 
vs placebo) during pregnancy, with intervention starting at antenatal booking at <30weeks 6 
gestational age [50]. The study was conducted in the late 1960s and recently Richmond and 7 
colleagues [35] followed-up on the offspring born to the mothers who had participated in the 8 
trial, mean present age 47 years. Saliva samples were collected from those who could be 9 
identified and consented, with subsequent 450k array analysis conducted using modelling 10 
approaches to correct for hidden variables such as cell counts [35]. Examination of the CpG in 11 
the ZFP57 DMR which we had identified in the EpiFASSTT cohort showed the same trends 12 
in the AFAST high-folate cohort versus placebo, with change in a positive direction across the 13 
whole region (Fig.5A), although effect size was lower at each site in the AFAST study 14 
(Fig.5B).  15 
Discussion 16 
We have previously reported DNA methylation differences at imprinted loci using cord blood 17 
from the EpiFASSTT trial of folic acid (FA) supplementation in later pregnancy by using a 18 
candidate gene approach. Here we used the same samples to carry out an unbiased genome-19 
wide screen for methylation differences using the EPIC array. The top hit was a differentially 20 
methylated region upstream of the imprint controller ZFP57 and we separately verified 21 
methylation differences by pyroassay. This region responded to FA supplementation in 22 
maternal blood as well as in cord blood, and showed differences between FA-treated and 23 
untreated in an independent cohort [50]. Altered methylation at ZFP57 was associated with 24 
increased variation in methylation at imprinted loci in cord blood. We also showed using two 25 
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separate cell line models that altering methylation at the ZFP57 upstream region can affect 1 
transcription, indicating a potential feedback mechanism may be operating here. We were also 2 
able to identify and verify methylation changes at a number of other individual CpG sites 3 
including some in the gene bodies of the NXN and PRKAR1B genes and at the start of the 4 
MIR4520A/B gene, but these were less likely to have functional consequences. It is notable 5 
also that we found more decreases in methylation genome-wide than increases, which may 6 
seem counter-intuitive; however we and others have reported similar response to FA previously 7 
[43, 56]. It is has been suggested that FA may cause feedback inhibition by altering the 8 
SAM:SAH ratio and therefore the intracellular methylation potential [51].  9 
Uncovering a DMR at a region controlling ZFP57 transcription as the top hit in an 10 
unbiased screen was particularly striking in the EpiFASSTT randomized controlled trial, where 11 
we have already shown, using a candidate gene approach, that methylation levels were 12 
perturbed at some imprinted loci. The primary importance of ZFP57, as described in the 13 
literature from mechanistic work, is in maintaining imprinting, and it is currently the only 14 
protein known to be dedicated solely or largely to this epigenetic process [52]. ZFP57 was 15 
discovered as a maternal-zygotic effect gene which was required in mice for establishing 16 
methylation at some imprints in the oocyte, and for maintaining all imprints, both maternal and 17 
paternal, in the preimplantation embryo [38]. It does this by binding to a conserved hexamer 18 
consensus sequence (5’-TGCme5CGC-3) found at all imprinting control regions (ICRs) 19 
[53,54], recognizing the methylated CpG in this motif, as shown in a crystallographic study 20 
[55].  Deletion of mouse Zfp57 causes a loss of methylation from the modified parental allele 21 
by mid-gestation, with subsequent dysregulation of transcription at imprinted loci and 22 
embryonic lethality [54]. Importantly, mutations in the human homologue ZFP57 are also 23 
associated with hypomethylation of multiple imprinted loci, indicating a conserved role in 24 
human for this gene in maintaining imprints [39].  25 
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Although this is the first report, to our knowledge, from a randomized controlled trial 1 
of FA intervention which implicates methylation changes at ZFP57, it was previously reported 2 
from a small observational study (n=23) that maternal folate concentrations in the third 3 
trimester were associated with changes at a DMR at  the same genomic location [56] when 4 
cord blood DNA methylation levels at birth were profiled. While that study reported a loss 5 
rather than gain of methylation, it was not an RCT but an observational study, and so could not 6 
test the effects of folate supplementation directly in a controlled fashion: there were many other 7 
differences in study design, numbers of participants and analysis methods. It should also be 8 
noted that the high folate group in that study had levels of serum folate almost twice those seen 9 
in our treated samples (74.59+/- 6.1 nmol/L Amarasekera et al. vs 46.5 +/-19.5 nmol/L GW36 10 
treated group this study), highlighting that we are protecting normal folate levels rather than 11 
elevating them. Although the largest-to-date observational study, comprising a meta-analysis 12 
of the MoBa (n=1275) and Generation R (n=713) cohorts, did not identify this region as a top 13 
hit, they could confirm that 5 CpG sites within this 923bp region were significantly altered, 14 
though not the direction of change [57]. These two papers reporting changes from different 15 
observational studies nevertheless lend considerable support to this being a true folate-sensitive 16 
DMR. We could also verify using a separate biological assay the magnitude and direction of 17 
change in methylation, a gain of 5.44% in the treatment group, at the DMR in cord blood by 18 
using pyrosequencing (p = 0.172). Furthermore, by comparing the mothers pre- and post-19 
intervention we could show that this region also gained methylation in the treated mothers, but 20 
lost methylation in the placebo group, providing a further degree of validation.  21 
To extend our findings, we also used data from one of the few other RCT testing the 22 
role of folic acid during pregnancy, the AFAST study [50]. We found a small effect (Cohen’s 23 
D<0.2) at all the CpG across the ZFP57 DMR, whereas there was a medium effect (Cohen’s D 24 
<0.5) seen at the same region in the EpiFASSTT study. The effect in AFAST was only seen 25 
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with the high dose of FA (5mg/day) vs placebo, rather than the lower dose (200g/day) which 1 
was closer to that used in EpiFASSTT (400g/day), and the effect size was smaller than that 2 
seen in EpiFASSTT. There may be a number of reasons why effect size was smaller in AFAST: 3 
1)the time between exposure and measurement is much greater, with median age 47 years in 4 
AFAST, vs newborns in EpiFASSTT; 2)the AFAST participants used were recruited 5 
significantly later than other groups (20.2 weeks for high dose vs 16.3 for low dose), meaning 6 
that there was less time spent exposed to the additional FA while in the womb 3)the AFAST 7 
DNA samples were derived from saliva, while the EpiFASSTT DNA samples are from cord 8 
blood  and 4)final numbers for the AFAST comparisons were very low (5mg/day n=23; placebo 9 
n=43). Notwithstanding these limitations, the AFAST study showed a similar effect in terms 10 
of direction and magnitude at the same region upstream of ZFP57, providing further evidence 11 
that this is a bona fide FA sensor.   12 
Given the role of ZFP57 in imprint maintenance, we also took advantage of the array 13 
to examine imprinted genes in our samples.  Of these, only the maternal imprint NNAT 14 
(neuronatin) showed a small but significant loss of methylation in the treatment group, 15 
consistent with other evidence [58]. NNAT is highly expressed in brain and placental tissue and 16 
functions during brain development to regulate ion channels and maintain hindbrain and 17 
pituitary segment identity [59]. ZFP57 is essential for the maintenance of this imprint [38]. 18 
Induction of increasing mRNA levels of NNAT commences at midgestation in association with 19 
neurogenesis, and peaks upon neuroepithelial proliferation and neuroblast formation [60], 20 
which would coincide with  when folate concentrations increased in the treated group. 21 
Although we previously reported  significant differences overall at IGF2, and at some CpG for 22 
GRB10 in our candidate gene approach using these samples [43], that was based on pyroassays 23 
which covered smaller regions of the imprinted DMR, whereas the probes from the array are 24 
more dispersed and cover a larger area.  It was also notable that, while there was little change 25 
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at other imprinted DMR as assessed by the array, there did appear to be an increase in the 1 
variability of methylation at these regions, an effect which was small but statistically significant 2 
and consistent with findings from a mouse model where FA supplementation increased 3 
variance in methylation levels across generations [61]. Given that ZFP57 has a role in 4 
maintaining imprints, increased methylation at the upstream controller as seen in our FA-5 
treated samples should lead to decreased transcription of ZFP57, which could potentially lead 6 
to reduced ability to maintain imprints and increased variability in methylation at the ICR. 7 
These possibilities can be further explored using our in vitro cell models.  8 
It remains to be established from mechanistic studies in mouse whether ZFP57 plays 9 
any role in maintaining methylation in vivo in the post-implantation embryo. It is also possible 10 
that methylation of the DMR in human blood may not reflect the methylation levels seen at 11 
earlier stages, or in tissues which normally express the gene, which includes oocytes and some 12 
neural cells. It may be that methylation levels at the ZFP57 DMR reported here reflect changes 13 
which have occurred in cord and maternal bloods independently of what is occurring in 14 
germline, and this would need to be assessed. It is also quite likely, given that imprints are 15 
thought to be established much earlier during development that it would not be until the next 16 
generation that effects at imprinted germline DMRs could be seen. In this context, several 17 
studies have pointed to transgenerational rather than intergenerational effects at imprinted loci 18 
[62,63]. It should also be noted that methylation levels varied substantially across the ZFP57 19 
DMR and between individuals (max = 94.97, min = 20.95), unlike the imprinted DMR which 20 
vary much less and may be buffered against methylation changes by multiple mechanisms.  21 
In addition to its well-established role in imprinting, ZFP57 has also been proposed to 22 
act as a transcriptional repressor in Schwann cells, which comprise the principal glia of the 23 
peripheral nervous system [47]. Recent work from our group has indicated children born from 24 
mothers supplemented with FA in late gestation have psychosocial developmental benefits, 25 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 17 of 38 
 
scoring significantly higher for emotional intelligence and resilience in comparison with 1 
children not exposed to FA supplementation in later pregnancy [64]. Further work needs to 2 
be carried out to check if there are any other, novel targets of ZFP57 which may be affected 3 
in later childhood and adulthood.  4 
We sought to clarify whether an increase in methylation at the ZFP57 DMR as seen in 5 
this RCT would have a substantial effect on production of the protein. In order to explore 6 
whether changes in methylation can alter transcription we utilized cell lines where the only 7 
variable was the presence or absence of DNA methylation. Our results from these two systems 8 
(HCT116 cells with methyltransferase deficiency and SH-SY5Y cells treated with an inhibitor) 9 
showed that altering methylation alone can cause changes in transcription at the ZFP57 locus, 10 
and that this is linked to changes in methylation at the DMR. Our results therefore support the 11 
hypothesis that the DMR represents an upstream control element for the gene, which we have 12 
shown from the RCT is sensitive to methyl donor status in the diet. Little is currently known 13 
about the factors controlling ZFP57 transcription. Interestingly, the region containing the DMR 14 
does not appear to be conserved in mice, and so may represent a human-specific element. 15 
However it has features characteristic of a control element, as from examining publicly-16 
available datasets on the UCSC genome browser there are DNAse I hypersensitive sites present 17 
here and data suggesting transcription factors may bind. We are currently exploring these 18 
aspects of the work further.  19 
Conclusions 20 
Despite the limitations discussed above, we have nevertheless shown conclusively that a region 21 
upstream of the imprint controller ZFP57 shows changes in methylation in mothers in response 22 
to intervention during later pregnancy with FA, a methyl donor, and that this effect is also 23 
evident in the cord blood in their offspring. Our findings are borne out by other observational 24 
studies as well as an independent RCT [50]. We have also clearly demonstrated that altering 25 
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methylation is sufficient in itself to cause changes in transcription of the gene. These results 1 
have implications for the control of imprinting by environmental inputs and uncover a novel 2 
transcriptional control element which may be involved in this process.   3 
Methods 4 
Study design and sample collection  5 
Samples were acquired from the FASSTT (Folic acid supplementation in the second and third 6 
trimester) study cohort, a previously-conducted double-blinded, randomized controlled trial in 7 
Northern Ireland described in full previously [42,43]. To summarize in brief, women with 8 
singleton pregnancies were recruited at approximately 14 weeks of gestation from antenatal 9 
clinics at the Causeway Hospital, Coleraine (n = 226; Fig.1). Women were excluded from 10 
participation if they were taking medication known to interfere with B-vitamin metabolism or 11 
if they had any vascular, renal, hepatic or gastrointestinal disease, epilepsy or had a previous 12 
NTD-affected pregnancy. Prior to randomization, n=36 women withdrew from the study. The 13 
remaining eligible participants at the end of their first trimester were randomized into two 14 
groups; one group received 400µg/d folic acid (n = 96) and the other a placebo in pill form (n 15 
= 94) until the end of their pregnancy. Randomization was done on a double-blind basis. 16 
Maternal non-fasting blood samples were taken at gestational week 14 (GW14), prior to 17 
intervention commencement, and at GW36, towards the end of the intervention. The study was 18 
completed by 119 women, as 71 participants were excluded during the study (see Fig.1). A 19 
total of n=37 women were excluded from the folic acid group for the following reasons: 20 
participant withdrawal n=11, pregnancy complications n=13, prescribed folic acid n=6, foetal 21 
death n=6, non-compliance n=6. A total of n=34 women were excluded from the folic acid 22 
group for the following reasons: participant withdrawal n=14, pregnancy complications n=8, 23 
prescribed folic acid n=5, foetal death n=2, non-compliance n=3, hospital transfer n=2. 24 
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Umbilical cord blood samples were collected after the expulsion of the placenta at delivery, 1 
along with birth weight, length, head circumference, mode of delivery and Apgar score. 2 
Blood sample processing and B-vitamin biomarker determination 3 
Blood samples were collected in EDTA-lined tubes, kept refrigerated and processed within 4h 4 
(excepting cord blood, processed within 24h). Blood samples were analyzed for serum and red 5 
blood cell folate and vitamin B12 via microbiological assay as previously described [65,66] . 6 
The buffy coat was used for methylenetetrahydrofolate reductase (MTHFR) 677C>T 7 
genotyping as described (Frosst et al. 1995). Quality control was affirmed by repeated analysis 8 
of stored batches of pooled samples. Intra- and inter-assay CVs were ≤8.2% for serum and 9 
RBC folate and ≤10.4% for serum vitamin B12. 10 
Maternal dietary analysis  11 
Dietary data was collected using a 4d food diary in combination with a food-frequency 12 
questionnaire during the second trimester of pregnancy, with particular emphasis on a of B-13 
vitamin-fortified food intake. Dietary analysis was carried out using WISP version 3.0 14 
(Tinuviel Software, UK) modified to segregate naturally-occurring folate in foods versus folic 15 
acid fortification of foods; these were combined to enable calculation of dietary folate 16 
equivalents. 17 
Cell culture 18 
HCT116 and double knockout (DKO) cells (Rhee et al. 2002) were cultured in 1g/L glucose 19 
DMEM supplemented with 10% FBS and 1x NEAA (Thermo Scientific, Loughborough, UK). 20 
SH-SY5Y cells were cultured in DMEM/F12 medium supplemented with 10% FBS (Thermo 21 
Scientific) For treatment with 5’aza-2-deoxycytidine (5-aza-dC) (Sigma-Aldrich, Dorset, UK), 22 
SH-SY5Y cells were seeded onto a 90mm plate in complete medium, and the following day 23 
medium was replaced and supplemented with 5-aza-dC at a final concentration of 1μM, which 24 
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was renewed at 24-hour intervals up to 72 hours. Cells were then harvested for DNA and RNA 1 
extraction.  2 
Transcriptional analysis 3 
RNA was extracted using the RNeasy Mini kit (Qiagen, Crawley, UK) according to 4 
manufacturer’s instructions. Complementary DNA (cDNA) was synthesized and RT-5 
qPCR/RT-PCR were carried out as previously [29]. Primer sequences are listed in 6 
Supplementary Table 1. Human reference total RNA was used as a positive control for 7 
expression (Clontech, UK). 8 
DNA extraction, bisulfite conversion and Infinium MethylationEPIC Beadchip Array 9 
Genomic DNA was extracted from cultured cells as previously described [25] and from cord 10 
blood using the QiAMP DNA Blood Mini kit (Qiagen), according to manufacturer’s 11 
instructions. Purity and integrity of DNA were assessed by agarose gel electrophoresis and 12 
using the Nanodrop 2000 spectrophotometer (Labtech International, Ringmer, UK). DNA 13 
quantification was determined using Quant-IT PicoGreen dsDNA Assay Kit (Invitrogen, 14 
Paisley, UK). The DNA at a concentration of 50ng/l was sent to Cambridge Genomic Services 15 
(Cambridge, UK), who bisulfite converted the DNA in-house using the EZ DNA Methylation 16 
Kit (Zymo Research, California, USA) prior to hybridization to the  Infinium Human 17 
Methylation EPIC BeadChip Array and scanning with the Illumina iScan according to 18 
manufacturer’s instructions (Illumina, Chesterford, UK).  19 
Bioinformatic analysis 20 
GenomeStudio (Illumina v3.2) was used for initial data processing. Subsequently idat files 21 
were imported into the RnBeads package (version 1.6.1) [45] in the freely available statistical 22 
software platform R (version 3.1.3) using R Studio interface (Version 0.99.903). Samples were 23 
quality control checked including removal of probes with missing values, containing SNPs, or 24 
of poor quality using the greedycut algorithm, then sex chromosomes were removed from the 25 
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analysis. Background correction was carried out using methylumi.noob and the methylation 1 
values of the remainder probes were normalized using bmiq [67]. Initial data exploration in 2 
RnBeads used principle components analysis (PCA) to explore potential correlations between 3 
the groups and known confounders such as BMI, smoking, gender etc. In addition, in order to 4 
account for any hidden confounding variables in the dataset, surrogate variable analysis was 5 
carried out using the sva package with the Buja and Eyboglu algorithm from (1992) [68]. 6 
Briefly, potential surrogate variables such as age, sample plate, Sentrix ID and Sentrix Position 7 
were tested for association with the target variable sample group using PCA  and any surrogate 8 
variable with a high correlation to sample group was adjusted for and incorporated into the 9 
making of the limma based linear model. The methylation intensities for each probe, each 10 
representing a CpG site, were represented as β-values (ranging from 0, unmethylated, to 1, 11 
fully methylated) and these were plotted against genomic loci (based on hg19 -Human Genome 12 
Build 19) using GALAXY software (https://usegalaxy.org/) [69] in order to visualize changes 13 
in DNA methylation on the University of California at Santa Cruz genome browser 14 
(https://genome.ucsc.edu/) as described previously [70]. 15 
Bisulfite pyrosequencing 16 
Primers spanning the probes of interest from the array were designed using the PyroMark 17 
Assay Design Software 2.0 and bisulfite-treated DNA PCR-amplified using the PyroMark PCR 18 
kit prior to analysis on a PyroMark Q24 according to manufacturer’s instruction (Qiagen). The 19 
primer sequences are summarized in Supplementary Table 2. Amplification was carried out as 20 
follows: 95°C for 15min, followed by 45 cycles of 95°C for 30sec, 56°C for 30 sec, and 72°C 21 
for 30sec, with a final elongation step at 72°C for 10min. Products were verified via gel 22 
electrophoresis prior to pyrosequencing analysis.  23 
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Statistical analysis 1 
Statistical analysis was performed using the Statistical Package for the Social Sciences 2 
software (SPSS) (Version 22.0; SPSS UK Ltd., Chertsey, UK). The results are expressed as 3 
mean ± SD, except where otherwise stated. For normalization purposes, variables were log 4 
transformed before analysis, as appropriate. Differences between treatment groups for 5 
participant characteristics were assessed using an independent t test for continuous variables or 6 
chi-square for categorical variables. Pyrosequencing data and RT-qPCR data were analyzed 7 
using Student’s t test to identify statistical differences between intervention groups. A p value 8 
<0.05 was considered significant. Differential methylation analysis was conducted in RnBeads 9 
(see above) on a site and region level. The normalized β-values were converted into M-values 10 
(M = log2(β/(1-β)) and differential methylation between samples (placebo vs. treatment) was 11 
estimated with hierarchical linear models using limma. Ranking was automatically carried out 12 
in RnBeads and was based on the combination of the average difference in means across all 13 
sites in the promoter regions of the sample groups, the mean of quotients in mean methylation 14 
and the combined p-value, which was calculated from all site p-values in the region using a 15 
generalization of Fisher's method [71]. The smaller the combined rank for a region, the more 16 
evidence for differential methylation it exhibits.   17 
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Table 1 General characteristics of participants from the EpiFASSTT trial 1 
Characteristic Placebo  Folic Acid  P value1 
N 45 41  
Maternal characteristics (GW14) Mean SD Mean SD  
Age (y) 28.9 3.5 29.4 3.9 0.513 
BMI (kg/m2) 25.2 3.9 24.9 4.6 0.768 
Smoker n (%) 8 (18) 6 (15) 0.693 
Alcohol n (%) 3 (7) 1 (2) 0.618 
Parity (n) 1 (1.1) 1 (1.0) 0.915 
MTHFR 677TT genotype n (%) 5 (11) 2 (5) 0.291 
Dietary Intakes 
Energy (MJ/d) 8.170 1.717 7.732 1.595 0.280 
Dietary Folate Equivalents (µg/d) 364 172 387 152 0.582 
Vitamin B12 (µg/d) 4.1 1.9 3.9 1.8 0.791 
Neonatal characteristics 
Gestational age (wk) 40.1 1.3 40.0 1.1 0.540 
Sex, Male n (%) 22 (49) 22 (54) 0.659 
Birth weight (g) 3610 475 3557 465 0.601 
Birth length (cm) 51.5 2.6 51.1 2.2 0.499 
Head circumference (cm) 34.9 1.2 34.8 1.4 0.907 
Apgar score at 5 min 8.4 0.4 9.0 0.3 0.220 
Caesarian n (%) 11 (24) 10 (24) 0.995 
B-vitamin Biomarkers 
Maternal pre-intervention (GW14) 
Serum folate (nmol/L) 48.8 19.8 45.8 19.5 0.469 
RBC folate (nmol/L) 1185 765 1181 649 0.978 
Serum B12 (pmol/L) 224 79 217 79 0.601 
Maternal post-intervention (GW36) 
Serum folate (nmol/L) 23.6 17.9 46.5 24.8 <0.001* 
RBC folate (nmol/L) 991 404 1556 658 <0.001* 
Serum B12 (pmol/L) 168 51 157 60 0.229 
Cord Blood 
Serum folate (nmol/L) 68.3 24.8 91.7 36.7 0.004* 
RBC folate (nmol/L) 1518 597 1877 701 0.024* 
Serum B12 (pmol/L) 276 155 251 107 0.776 
 2 
Statistical comparisons by independent t test (continuous variables) or χ2 test (categorical 3 
variables). *P < 0.05. GW, gestational week; BMI, body mass index; RBC, red blood cell. 4 
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Table 2 ZFP57 methylation in maternal blood pre- and post-intervention 1 
DNA methylation levels of ZFP57 DMR in maternal blood samples at GW14 and GW36. GW, 2 
gestational week; SD, standard deviation 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
Sample Group 
Gestational Week 
(GW) 
Mean 
Methylation 
(%) 
Standard 
Deviation 
(SD) 
Change in 
methylation (%) 
Treatment 
(n=24) 
GW14 57.47 15.37 
+5.51 
GW36 62.98 14.94 
Placebo 
(n=24) 
GW14 64.36 6.58 
-1.51 
GW36 62.85 7.13 
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Figure Legends 1 
Figure 1 FASSTT study outline for samples used in this study 2 
Eligible pregnant women (n=226) were randomized into two groups: Placebo (n=94) and Folic 3 
acid (n=96). Women withdrew (n=25) or were excluded from the intervention for the reasons 4 
indicated. A total of 119 women completed the trial. Blood samples were taken at gestation 5 
weeks (GW) 14 (pre-intervention) and 36 (post-intervention). Cord blood samples (n=86) were 6 
taken at birth.  7 
Figure 2 Widespread alterations to DNA methylation levels in cord blood in response to 8 
late gestation maternal folic acid supplementation  9 
(A) Scatterplot comparing mean methylation levels ( values: 1=100%; 0=0% methylation) at 10 
individual probes in placebo and treated groups. The 1000 top ranking sites between groups 11 
are highlighted in red:  = correlation value. (B) Probe methylation density plot comparing the 12 
distributions of methylation values per sample group. In the treatment group there is a decrease 13 
in the number of fully methylated sites (β >0.75). (C) Split in top 1000 ranking sites losing or 14 
gaining methylation overall. Also shown are numbers of sites showing changes greater than 15 
5% or 10%. (D) Top 5 differentially methylated sites overall, sorted by combined rank, the 16 
value being computed as the maximum (i.e. worst) value amongst the mean quotient log, mean 17 
difference in methylation and p value (P). No., number; Chr, chromosome; Position, 18 
coordinates in hg19 human genome release; CG probe, identity number of the probe on the 19 
EPIC array; % change, difference in mean value expressed as %; Gene, nearest gene; P, 20 
probability (uncorrected); Rank, RnBeads computed ranking value (lowest being best). 21 
Figure 3 Top ranking promoter regions included imprint regulator gene ZFP57 22 
((A) Top 5 differentially methylated regions (DMR) at promoters, sorted by combined 23 
RnBeads rank (smallest to largest) as for Fig.2D above, except combining values across all the 24 
CG sites in the DMR as detailed in Methods. Abbreviations as above except # probes, number 25 
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of probes on EPIC array included in DMR. (B) Top: Genome browser tracks showing the 1 
region around the DMR upstream of ZFP57, genomic coordinates in hg19 human genome 2 
release and scale as shown. EPIC array probes showing differential methylation (blue, gain; 3 
red, loss) are indicated, with size indicating magnitude of change. The start of the ZFP57 gene 4 
and the position of the pyrosequencing assay (Pyro) are also shown. , mean difference in  5 
value between placebo and FA-treated groups; maximum gain and loss also shown (+0.09  = 6 
9% methylation). Bottom: Loess plot of  values across the region, with CpG identification 7 
numbers from array below; those forming the DMR defined by RnBeads are indicated, as well 8 
as sites analyzed by pyroassay. Each dot represents  value in an individual sample, with lines 9 
representing smoothed averages; color code is indicated at left. (C) Results of pyroassay 10 
covering the 6 sites indicated in B. Sample groups: cord blood DNA from placebo (n=45) and 11 
FA-treated (n=41). Mean, average of the individual means in that group; Max., largest of the 12 
mean methylation values in that group; Min, lowest mean in group; SD, standard deviation for 13 
the means; Change, difference in % methylation seen between groups; P, probability (Student’s 14 
t-Test). 15 
Figure 4 ZFP57 upstream region is a methylation-dependent regulator of transcription 16 
at this locus 17 
(A) Schematic as in Fig.3 above but showing difference in methylation () between HCT116 18 
WT cells vs HCT116 DKO cells. The intron/exon structure and positions of the forward (FW) 19 
and reverse (RV) primers for RT-(q)PCR on the ZFP57 gene are also shown. (B) Methylation 20 
levels at individual CpG covered by the pyrosequencing assay in WT (HCT116) and knockout 21 
(DKO) cells. Values are shown as mean +/- SD for each site: *P<0.05; **P<0.01; 22 
***P<0.001. (C) RT-PCR showing up-regulation using the primers indicated in A, key as 23 
above. CTRL, positive control (human reference total RNA); NTC, negative control (no 24 
template control); 100bp, size standards ladder; ACTB, -actin loading control. (D) 25 
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Confirmation of upregulation by RT-qPCR using the same primers, values normalized to 1 
HPRT; FC, fold change. (E) Methylation levels using pyroassay as in B but in 5-aza-dC treated 2 
SH-SY5Y cells (5-aza-dC), as compared to untreated (UT). (F) RT-PCR for 5-aza-dC treated 3 
cells from E. (G) RT-qPCR confirmation of ZFP57 upregulation in 5-aza-dC-treated SH-SY5Y 4 
cells.  5 
Figure 5 Comparison of AFAST and EpiFASSTT data for the DMR  6 
(A)Effect size (Cohen’s D) at each CpG in the ZFP57 DMR was calculated by comparing high 7 
dose and placebo from the AFAST study and plotted against the locus (top track). A similar 8 
analysis was done for the EpiFASSTT data (bottom track). Maxima are indicated at right, scale 9 
bar and location at top: note- no other CpG outside the DMR are shown in this analysis. (B)The 10 
two sets of values from A are plotted on the same scale to give an indication of comparability.  11 
Supplementary Table 1 Pyrosequencing and transcriptional primer sets used in this study 12 
Pyroassay primers are given as bisulfite converted sequence. The same primers were used for 13 
both RT-PCR and RT-qPCR.    14 
Supplementary Figure 1 Correlation between folate levels in cord blood and mother 15 
Scatterplot shows log-converted red blood cell folate (RCF) levels in nanomoles per liter 16 
(nmol/l) at gestational week 36 (GW36) for mothers (post-intervention) and matched cord 17 
blood. The line of best fit shows significant correlation between mothers and offspring (r = 18 
0.619; P = <0.001). 19 
Supplementary Figure 2 QQ plot shows no evidence of population substructure effects 20 
The observed Chi-squared (2) values (open circles), plotted as –log10 of the p value for both 21 
sample groups, fit tightly to the expected 2 values (red line), indicating little evidence of 22 
association due to population substructure effects and that the top hits which deviate from the 23 
line (right-hand side) are likely to represent true differences due to loci with large effects.  24 
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Supplementary Figure 3 Median methylation levels at imprint control regions  1 
Methylation levels at imprint control regions (ICR) were assessed by matching EPIC array 2 
probes to the imprint germline DMR intervals defined by [48] (A) or [49] (B) then taking the 3 
average (median) across each. The identities of each ICR and number of probes are indicated 4 
below. Boxes show the median and interquartile range for the individual averages from each 5 
group (Placebo n=45, Treated n=41), whiskers represent the range of values, dots indicate 6 
outliers.  7 
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